{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:02:53Z","timestamp":1779242573625,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,2,11]],"date-time":"2011-02-11T00:00:00Z","timestamp":1297382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1007\/s11239-011-0556-y","type":"journal-article","created":{"date-parts":[[2011,2,10]],"date-time":"2011-02-10T04:42:06Z","timestamp":1297312926000},"page":"59-63","source":"Crossref","is-referenced-by-count":18,"title":["Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy"],"prefix":"10.1007","volume":"32","author":[{"given":"Mehmet","family":"Agirbasli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mesut","family":"Eren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Eren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila B.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zehra A.","family":"Serdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilek","family":"Seckin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuba","family":"Zara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cem Mat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuyan","family":"Demirkesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas E.","family":"Vaughan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,11]]},"reference":[{"key":"556_CR1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/archderm.134.4.491","volume":"134","author":"JL Jorizzo","year":"1998","unstructured":"Jorizzo JL (1998) Livedoid vasculopathy: what is it? Arch Dermatol 134:491\u2013493","journal-title":"Arch Dermatol"},{"key":"556_CR2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/archderm.140.8.1011","volume":"140","author":"C Franc\u00e8s","year":"2004","unstructured":"Franc\u00e8s C, Barete S (2004) Difficult management of livedoid vasculopathy. Arch Dermatol 140:1011","journal-title":"Arch Dermatol"},{"key":"556_CR3","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/archderm.142.11.1413","volume":"142","author":"BR Hairston","year":"2006","unstructured":"Hairston BR, Davis MD, Pittelkow MR, Ahmed I (2006) Livedoid vasculopathy: further evidence for procoagulant pathogenesis. Arch Dermatol 142:1413\u20131418","journal-title":"Arch Dermatol"},{"key":"556_CR4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1001\/archderm.139.8.987","volume":"139","author":"BR Hairston","year":"2003","unstructured":"Hairston BR, Davis MD, Gibson LE, Drage LA (2003) Treatment of livedoid vasculopathy with low molecular weight heparin: report of 2 cases. Arch Dermatol 139:987\u2013990","journal-title":"Arch Dermatol"},{"key":"556_CR5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1034\/j.1600-0560.2000.027008410.x","volume":"27","author":"T Biedermann","year":"2000","unstructured":"Biedermann T, Flaig MJ, Sander CA (2000) Livedoid vasculopathy in a patient with factor V mutation (Leiden). J Cutan Pathol 27:410\u2013412","journal-title":"J Cutan Pathol"},{"key":"556_CR6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1001\/archderm.134.4.447","volume":"134","author":"M Papi","year":"1998","unstructured":"Papi M, Didona B, De Pita O, Frezzolini A, Di Giulio S, De Matteis W, Del Principe D, Cavalieri R (1998) Livedo vasculopathy vs small vessel cutaneous vasculitis: cytokine and platelet P-selectin studies. Arch Dermatol 134:447\u2013452","journal-title":"Arch Dermatol"},{"key":"556_CR7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2133.1999.02622.x","volume":"140","author":"KM Acland","year":"1999","unstructured":"Acland KM, Darvay A, Wakelin SH, Russell-Jones R (1999) Livedoid vasculitis: a manifestation of the antiphospholipid syndrome? Br J Dermatol 140:131\u2013135","journal-title":"Br J Dermatol"},{"key":"556_CR8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1067\/mjd.2002.117718","volume":"46","author":"KT Calamia","year":"2002","unstructured":"Calamia KT, Balabanova M, Perniciario C, Walsh JS (2002) Livedo (livedoid) vasculitis and the factor V Leiden mutation: additional evidence for abnormal coagulation. J Am Acad Dermatol 46:133\u2013137","journal-title":"J Am Acad Dermatol"},{"key":"556_CR9","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1046\/j.1365-2133.2000.03786.x","volume":"143","author":"A Boyvat","year":"2000","unstructured":"Boyvat A, Kundakci N, Babikir MO, Gurgey E (2000) Livedoid vasculopathy associated with heterozygous protein C deficiency. Br J Dermatol 143:840\u2013842","journal-title":"Br J Dermatol"},{"key":"556_CR10","first-page":"1003","volume":"128","author":"MD Tran","year":"2001","unstructured":"Tran MD, Becherel PA, Cordel N, Piette JC, Frances C (2001) \u201cIdiopathic\u201d white atrophy. Ann Dermatol Venereol 128:1003\u20131007","journal-title":"Ann Dermatol Venereol"},{"key":"556_CR11","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/archderm.142.11.1466","volume":"142","author":"A Deng","year":"2006","unstructured":"Deng A, Gocke CD, Hess J, Heyman M, Paltiel M, Gaspari A (2006) Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G\/4G) treated successfully with tissue plasminogen activator. Arch Dermatol 142:1466\u20131469","journal-title":"Arch Dermatol"},{"key":"556_CR12","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1111\/j.1538-7836.2005.01420.x","volume":"3","author":"DE Vaughan","year":"2005","unstructured":"Vaughan DE (2005) PAI-1 and atherothrombosis. J Thromb Haemost 3:1879\u20131883","journal-title":"J Thromb Haemost"},{"key":"556_CR13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1742-1241.2005.00379.x","volume":"59","author":"M Agirbasli","year":"2005","unstructured":"Agirbasli M (2005) Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract 59:102\u2013106","journal-title":"Int J Clin Pract"},{"key":"556_CR14","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1021\/bi00178a022","volume":"33","author":"DA Lawrence","year":"1994","unstructured":"Lawrence DA, Olson ST, Palaniappan S, Ginsburg D (1994) Engineering plasminogen activator inhibitor 1 mutants with increased functional stability. Biochemistry 33:3643\u20133648","journal-title":"Biochemistry"},{"key":"556_CR15","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1002\/j.1460-2075.1995.tb07299.x","volume":"14","author":"MB Berkenpas","year":"1995","unstructured":"Berkenpas MB, Lawrence DA, Ginsburg D (1995) Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J 14:2969\u20132977","journal-title":"EMBO J"},{"key":"556_CR16","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1161\/01.ATV.21.6.1071","volume":"21","author":"NJ Brown","year":"2001","unstructured":"Brown NJ, Murphey LJ, Srikuma N, Koschachuhanan N, Williams GH, Vaughan DE (2001) Interactive effect of PAI-1 4G\/5G genotype and salt intake on PAI-1 antigen. Arterioscler Thromb Vasc Biol 21:1071\u20131077","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"556_CR17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/01.CIR.0000023186.60090.FB","volume":"106","author":"M Eren","year":"2002","unstructured":"Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE (2002) Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 106:491\u2013496","journal-title":"Circulation"},{"key":"556_CR18","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00019501-200608000-00003","volume":"17","author":"D Agirbasli","year":"2006","unstructured":"Agirbasli D, Agirbasli M, Williams SM, Phillips JA (2006) Interaction among 5, 10 methylenetetrahydrofolate reductase, plasminogen activator inhibitor and endothelial nitric oxide synthase gene polymorphisms predicts the severity of coronary artery disease in Turkish patients. Coron Artery Dis 17:413\u2013417","journal-title":"Coron Artery Dis"},{"key":"556_CR19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s100670070032","volume":"19","author":"YB Oh","year":"2000","unstructured":"Oh YB, Jun JB, Kim CK, Lee CW, Park CK, Kim TY, Yoo DH, Kim SY (2000) Mixed connective tissue disease associated with skin defects of livedoid vasculitis. Clin Rheumatol 19:381\u2013384","journal-title":"Clin Rheumatol"},{"key":"556_CR20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/archderm.142.1.75","volume":"142","author":"CE Browning","year":"2006","unstructured":"Browning CE, Callen JP (2006) Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia. Arch Dermatol 142:75\u201378","journal-title":"Arch Dermatol"},{"key":"556_CR21","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0025-6196(12)60922-7","volume":"67","author":"KL Klein","year":"1992","unstructured":"Klein KL, Pittelkow MR (1992) Tissue plasminogen activator for treatment of livedoid vasculitis. Mayo Clin Proc 67:923\u2013933","journal-title":"Mayo Clin Proc"},{"key":"556_CR22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/hc3301.092803","volume":"104","author":"K Kaikita","year":"2001","unstructured":"Kaikita K, Fogo AB, Ma L, Schoenhard JA, Brown NJ, Vaughan DE (2001) Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 104:839\u2013844","journal-title":"Circulation"},{"key":"556_CR23","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1006\/jmcc.2002.2001","volume":"34","author":"K Kaikita","year":"2002","unstructured":"Kaikita K, Schoenhard JA, Painter CA, Ripley RT, Brown NJ, Fogo AB, Vaughan DE (2002) Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition. J Mol Cell Cardiol 34:617\u2013627","journal-title":"J Mol Cell Cardiol"},{"key":"556_CR24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1161\/01.ATV.11.1.183","volume":"11","author":"S Dawson","year":"1991","unstructured":"Dawson S, Hamsten A, Wiman B, Henney A, Humphries S (1991) Genetic variations at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasminogen activator inhibitor-1 activity. Arterioscler Thromb 11:183\u2013190","journal-title":"Arterioscler Thromb"},{"key":"556_CR25","doi-asserted-by":"crossref","first-page":"R1563","DOI":"10.1152\/ajpregu.00093.2009","volume":"297","author":"R Serrano","year":"2009","unstructured":"Serrano R, Barrenetxe J, Orbe J, Rodr\u00edguez JA, Gallardo N, Mart\u00ednez C, Andres A, P\u00e1ramo JA (2009) Tissue-specific PAI-1 gene expression and glycosylation pattern in insulin-resistant old rats. Am J Physiol Regul Integr Comp Physiol 297:R1563\u2013R1569","journal-title":"Am J Physiol Regul Integr Comp Physiol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-011-0556-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-011-0556-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-011-0556-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T12:44:28Z","timestamp":1559997868000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-011-0556-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,11]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["556"],"URL":"https:\/\/doi.org\/10.1007\/s11239-011-0556-y","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,11]]}}}